KR20230041021A - 이소퀴놀린 화합물 및 AhR 불균형 치료에 있어서 그의 용도 - Google Patents

이소퀴놀린 화합물 및 AhR 불균형 치료에 있어서 그의 용도 Download PDF

Info

Publication number
KR20230041021A
KR20230041021A KR1020237005000A KR20237005000A KR20230041021A KR 20230041021 A KR20230041021 A KR 20230041021A KR 1020237005000 A KR1020237005000 A KR 1020237005000A KR 20237005000 A KR20237005000 A KR 20237005000A KR 20230041021 A KR20230041021 A KR 20230041021A
Authority
KR
South Korea
Prior art keywords
optionally substituted
alkyl
compound
group
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237005000A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 에이치. 드류리
찬나 케이. 자야윅크레메
캐롤린 셀렌스키
수잔 에이치. 스미스
리안 폴 트럼프
캐로우 웰스
티모디 윌슨
쿤유 장
빌리암 추어처
앨리슨 액스트맨
Original Assignee
더마반트 사이언시즈 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더마반트 사이언시즈 게엠베하 filed Critical 더마반트 사이언시즈 게엠베하
Publication of KR20230041021A publication Critical patent/KR20230041021A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
KR1020237005000A 2020-07-16 2021-05-27 이소퀴놀린 화합물 및 AhR 불균형 치료에 있어서 그의 용도 Pending KR20230041021A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063052574P 2020-07-16 2020-07-16
US202063052561P 2020-07-16 2020-07-16
US63/052,574 2020-07-16
US63/052,561 2020-07-16
PCT/US2021/034599 WO2022015423A1 (en) 2020-07-16 2021-05-27 ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR IMBALANCE

Publications (1)

Publication Number Publication Date
KR20230041021A true KR20230041021A (ko) 2023-03-23

Family

ID=79293345

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237005000A Pending KR20230041021A (ko) 2020-07-16 2021-05-27 이소퀴놀린 화합물 및 AhR 불균형 치료에 있어서 그의 용도

Country Status (10)

Country Link
US (5) US11267788B2 (https=)
EP (1) EP4185566A4 (https=)
JP (1) JP2023533855A (https=)
KR (1) KR20230041021A (https=)
CN (1) CN116157387A (https=)
AU (1) AU2021308209A1 (https=)
CA (1) CA3185793A1 (https=)
IL (1) IL299756A (https=)
MX (1) MX2023000263A (https=)
WO (1) WO2022015423A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023533855A (ja) 2020-07-16 2023-08-04 ダーマヴァント サイエンシーズ ゲーエムベーハー イソキノリン化合物およびそのＡｈＲ不均衡の治療への使用
WO2024020170A1 (en) * 2022-07-21 2024-01-25 Allianthera (Suzhou) Biopharmaceutical Co., Ltd. Aryl hydrocarbon receptor agonist prodrugs and methods of use thereof
US20260069585A1 (en) * 2022-08-30 2026-03-12 Dermavant Sciences GmbH ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR MEDIATED DISEASES
WO2024152993A1 (zh) * 2023-01-17 2024-07-25 上海泽德曼医药科技有限公司 稠环类化合物、其制备方法及其在医药上的应用
CN117447402A (zh) * 2023-10-18 2024-01-26 德明药泰生物技术（深圳）有限公司 芳香烃受体调节剂类化合物及其制备方法和应用
CN117229208B (zh) * 2023-11-13 2024-02-23 上海泽德曼医药科技有限公司 稠环类化合物、其制备方法及其在医药上的应用
WO2026083733A1 (ja) * 2024-10-18 2026-04-23 株式会社ヤクルト本社 試験方法、ゲル状組成物、及び試験装置

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992018123A2 (en) 1991-04-10 1992-10-29 Octamer, Inc. A method for inhibition of retroviral replication
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
ATE404539T1 (de) * 1997-10-02 2008-08-15 Eisai R&D Man Co Ltd Kondensierte pyridinderivate
HRP20040102A2 (en) 2001-07-09 2004-10-31 Combinatorx Combinations for the treatment of inflammatory disorders
WO2003053359A2 (en) * 2001-12-19 2003-07-03 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
IL162533A0 (en) * 2001-12-19 2005-11-20 Atherogenics Inc Chalcone derivatives and their use to treat diseases
JPWO2005063222A1 (ja) 2003-12-26 2007-07-19 協和醗酵工業株式会社 Ｈｓｐ９０ファミリー蛋白質阻害剤
WO2006058201A2 (en) 2004-11-23 2006-06-01 Reddy Us Therapeutics, Inc. Heterocyclic and bicyclic compounds, compositions and methods
GB0704718D0 (en) 2007-03-12 2007-04-18 Prendergast Patrick T Compounds and methods for preventing and treating mucositis
EP2014651A1 (en) 2007-07-12 2009-01-14 Exonhit Therapeutics SA Compounds and methods for modulating Rho GTPases
JP5439127B2 (ja) 2009-11-13 2014-03-12 株式会社さいわいメディカル 乾癬又はアトピー性皮膚炎治療剤
WO2011156626A1 (en) 2010-06-09 2011-12-15 Rutgers, The State University Of New Jersey Antimicrobial agents
GB201216017D0 (en) * 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
AU2013361314A1 (en) 2012-12-20 2015-07-02 Aldeyra Therapeutics, Inc. Peri-carbinols
GB201304041D0 (en) 2013-03-06 2013-04-17 Water Jel Europ Llp Treatment and prophylaxis of radiation dermatitis
US10626094B2 (en) 2014-10-14 2020-04-21 Sanford Burnham Prebys Medical Discovery Institute Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof
JP7138654B2 (ja) * 2017-03-29 2022-09-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 金属錯体
US11548867B2 (en) * 2017-07-19 2023-01-10 Idea Ya Biosciences, Inc. Amido compounds as AhR modulators
EP3752512B1 (de) * 2018-02-13 2023-03-01 Merck Patent GmbH Metallkomplexe
TWI828664B (zh) 2018-03-19 2024-01-11 愛爾蘭商Ｕｄｃ愛爾蘭責任有限公司 金屬錯合物
JP2023533855A (ja) 2020-07-16 2023-08-04 ダーマヴァント サイエンシーズ ゲーエムベーハー イソキノリン化合物およびそのＡｈＲ不均衡の治療への使用
WO2023020512A1 (zh) * 2021-08-16 2023-02-23 成都奥睿药业有限公司 取代的吡啶类似物、其制备方法及作为ahr调节剂的用途
CN116947799B (zh) * 2023-03-08 2024-05-03 上海泽德曼医药科技有限公司 酚类化合物、其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
US20240208910A1 (en) 2024-06-27
EP4185566A4 (en) 2024-12-04
US20250282730A1 (en) 2025-09-11
MX2023000263A (es) 2023-03-29
US11827605B2 (en) 2023-11-28
AU2021308209A8 (en) 2023-04-13
IL299756A (en) 2023-03-01
CN116157387A (zh) 2023-05-23
AU2021308209A1 (en) 2023-02-09
US12252471B2 (en) 2025-03-18
CA3185793A1 (en) 2022-01-20
JP2023533855A (ja) 2023-08-04
WO2022015423A1 (en) 2022-01-20
US20220153703A1 (en) 2022-05-19
US11267788B2 (en) 2022-03-08
US11548853B2 (en) 2023-01-10
EP4185566A1 (en) 2023-05-31
US20230124135A1 (en) 2023-04-20
US20220017468A1 (en) 2022-01-20

Similar Documents

Publication Publication Date Title
KR20230041021A (ko) 이소퀴놀린 화합물 및 AhR 불균형 치료에 있어서 그의 용도
EP3252058B1 (en) Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections
WO2022017444A1 (zh) Shp2抑制剂及其组合物和应用
WO2017129116A1 (zh) 吡咯嘧啶五元氮杂环衍生物及其应用
JP2003535123A (ja) 治療薬としてのバルビツール酸類似体
US11299497B2 (en) Substituted tetrahydropyran dihydrothienopyrimidines and their use as phosphodiesterase inhibitors
US11384096B2 (en) Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors
CN107880038A (zh) [1,2,4]三唑并[1,5‑a]吡啶类化合物及其制备方法和医药用途
CN104011048A (zh) 作为磷酸二酯酶抑制剂的[1,2,4]三唑并吡啶类化合物及其应用
WO2014013182A1 (fr) Derive d'imidazopyridine utiles dans le traitement du diabete
KR20220166745A (ko) 펜드린 억제 활성을 갖는 신규 화합물 및 이의 의약 용도
WO2019085978A1 (zh) 杂芳基酰胺类化合物、其制备方法、药用组合物及其应用
EP4598631A1 (en) Methods of preparing carbamate derivatives
CA3085992A1 (en) Aldh2 activator
CN117999072A (zh) β肾上腺素能激动剂和其使用方法
US9896415B2 (en) Chalcone derivatives having an anti-allergic activity
KR101634758B1 (ko) 에스트로겐 수용체 리간드로서의 2-하이드록시-7-메틸 옥타하이드로페난트렌 유도체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 약학 조성물
JP2025523100A (ja) 二縮合環系ｍａｔ２ａ阻害剤およびその使用
JPH08268949A (ja) ジフェニルメチレン誘導体
HK40039957B (en) Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors
HK40039957A (en) Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902